Differential effects of inhaled and intravenous sildenafil in the prevention of the pulmonary endothelial dysfunction due to cardiopulmonary bypass

Journal of Cardiovascular Pharmacology

Volumn 51, Issue 1, 2008, Pages 11-17

  Aubin, Marie Claude ^a   Laurendeau, Steve ^b   Mommerot, Arnaud ^b,c   Lamarche, Yoan ^b   Denault, André ^b   Carrier, Michel ^b   Perrault, Louis P ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Cardiopulmonary bypass; Endothelium; Inflammatory response; Pulmonary arterial pressure

Indexed keywords

ACETYLCHOLINE; BRADYKININ; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FEMALE; LUNG ARTERY PRESSURE; LUNG ENDOTHELIUM; LUNG HEMODYNAMICS; LUNG PERFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; SWINE;

EID: 38349134572     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181598279     Document Type: Article

References (27)

1. Kolff WJ, Effler DB, Groves LK, et al. Pulmonary complications of open-heart operations: their pathogenesis and avoidance. Cleve Clin Q. 1958;25:65-83.
2. Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest. 1997;112:676-692.
3. Davila-Roman VG, Waggoner AD, Hopkins WE, et al. Right ventricular dysfunction in low output syndrome after cardiac operations: assessment by transesophageal echocardiography. Ann Thorac Surg. 1995;60:1081-1086.
4. Chen YF, Oparil S. Endothelial dysfunction in the pulmonary vascular bed. Am J Med Sci. 2000;320:223-232.
5. Lamarche Y, Malo O, Thorin E, et al. Inhaled but not intravenous milrinone prevents pulmonary endothelial dysfunction following CPB. J Thorac Cardiovasc Res. 2004;128:109-116.
6. Raja SG, Nayak SH. Sildenafil: emerging cardiovascular indications. Ann Thorac Surg. 2004;78:1496-1506.
7. Medina P, Segarra G, Martinez-Leon JB, et al. Relaxation induced by cGMP phosphodiesterase inhibitors sildenafil and zaprinast in human vessels. Ann Thorac Surg. 2000;70:1327-1331.
8. Trachte AL, Lobato EB, Urdaneta F, et al. Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann Thorac Surg. 2005;79:194-217.
9. Urdaneta F, Willert JL, Beaver T, et al. Effects of a new phosphodiesterase enzyme type V inhibitor (UK 343-664) versus milrinone in a porcine model of acute pulmonary hypertension. Ann Thorac Surg. 2004;78:1433-1437.
10. Tsai BM, Turrentine MW, Sheridan BC, et al. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression. Ann Thorac Surg. 2006;81:272-278.
11. Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation. 2001;104:424-428.
12. Shekerdemian LS, Ravn HB, Penny DJ. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med. 2002;165:1098-1102.
13. Ishikura F, Beppu S, Hamada T, et al. Effects of sildenafil citrate (Viagra) combined with nitrate on the heart. Circulation. 2000;102:2516-2521.
14. Traverse JH, Chen YJ, Du R, et al. Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise. Circulation. 2000;102:2997-3002.
15. Przyklenk K, Kloner RA. Sildenafil citrate does not exacerbate myocardial ischemia in canine model of coronary artery stenosis. J Am Coll Cardiol. 2001;37:286-292.
16. Riedel B. The pathophysiology and management of perioperative pulmonary hypertension with specific emphasis on the period following cardiac surgery. Int Anesthesiol Clin. 1999;37:55-79.
17. Morita K, Ihnken K, Buckberg GD, et al. Pulmonary vasoconstriction due to impaired nitric oxide production after cardiopulmonary bypass. Ann Thorac Surg. 1996;61:1775-1780.
18. Shafique T, Johnson R, Dai HB, et al. Altered pulmonary microvascular reactivity after total cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1993;106:479-486.
19. Gagnon J, Desjardins N, Malo O, et al. Mechanism of pulmonary artery endothelial dysfunction secondary to cardiopulmonary bypass. Can Perfusion. 2001;11:8-16.
20. Liu SF, Barnes PJ. Role of endothelium in the control of pulmonary vascular tone. Endothelium. 1994;2:11-33.
21. Fortier S, DeMaria RG, Lamarche Y, et al. Inhaled prostacyclin reduces cardiopulmonary bypass-induced pulmonary endothelial dysfunction via increased cyclic adenosine monophosphate levels. J Thorac Cardiovasc Surg. 2004;128:109-116.
22. McIntyre RC Jr, Mitchell MB, Campbell DN, et al. Lung transplantation with cardiopulmonary bypass exaggerates pulmonary vasomotor dysfunction in the transplanted lung. J Thorac Cardiovasc Surg. 1995;109:212-216.
23. Wessel DL, Adatia I, Giglia TM, et al. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation. 1993;88:2128-2138.
24. Kirklin JK, McGiffin DC. Control of the inflammatory response in extended myocardial preservation of the donor heart. Ann Thorac Surg. 1999;68:1978-1982.
25. Ratych R, Chuknyiska R, Bulkley G. The primary localization of free radical generation after anoxia/reoxygenation in isolated endothelial cells. Surgery. 1987;102:122-131.
26. Seccombe J, Schaff H. Coronary artery endothelial function after myocardial ischemia and reperfusion. Ann Thorac Surg. 1995;60:778-788.
27. Ichinose F, Roberts JD Jr, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation. 2004;109:3106-3111.